文献速递胸部肿瘤

Rova-T对比拓扑替康二线治疗DLL3高表达小细胞肺癌的III期TAHOE研究

Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.
PubMed 文献 · J Thorac Oncol · 2021-02-16

TAHOE是一项开放标签、2:1随机III期研究,在DLL3高表达晚期或转移性SCLC中比较Rova-T与拓扑替康二线治疗的疗效与安全性。Rova-T组中位OS为6.3个月,拓扑替康组为8.6个月(HR 1.46,95%CI 1.17-1.82),独立数据监查委员会因Rova-T组OS更短建议停止入组。Rova-T安全性特征与既往报告一致,但浆膜腔积液、光敏反应及外周水肿发生率更高。

要点

  • Rova-T二线治疗DLL3高表达SCLC的OS劣于拓扑替康(6.3 vs 8.6个月,HR 1.46)。
  • 独立数据监查委员会因Rova-T组OS更短建议停止入组。
  • Rova-T组浆膜腔积液、光敏反应及外周水肿发生率更高。

核心结论

  • 在DLL3高表达SCLC二线治疗中,Rova-T相比拓扑替康OS更差,且浆膜腔积液、光敏反应和外周水肿发生率更高。
  • 该人群仍存在显著的未满足治疗需求。

研究设计与样本

  • TAHOE为开放标签、2:1随机III期研究,比较Rova-T与拓扑替康二线治疗DLL3高表达晚期或转移性SCLC。
  • Rova-T 0.3 mg/kg静脉给药,42天为一周期,第1天给药,共2周期,符合方案继续给药标准者可再接受2周期。
  • 拓扑替康1.5 mg/m2静脉给药,21天为一周期,第1至5天给药。
  • 主要终点为总生存期(OS)。
  • Rova-T组296例、拓扑替康组148例纳入疗效分析;中位年龄64岁,77%初诊时为广泛期。

主要发现

  • Rova-T组中位OS为6.3个月(95%CI 5.6-7.3),拓扑替康组为8.6个月(95%CI 7.7-10.1),HR为1.46(95%CI 1.17-1.82)。
  • 独立数据监查委员会因Rova-T组OS更短建议停止入组。
  • 两种药物的安全性特征与既往报告一致。
  • Rova-T组浆膜腔积液、光敏反应及外周水肿发生率更高。

关键数值与推荐

  • Rova-T剂量为0.3 mg/kg,42天周期第1天静脉给药,共2周期,符合方案标准者可再接受2周期。
  • 拓扑替康剂量为1.5 mg/m2,21天周期第1至5天静脉给药。
  • 主要终点OS:Rova-T组6.3个月(95%CI 5.6-7.3)vs 拓扑替康组8.6个月(95%CI 7.7-10.1),HR 1.46(95%CI 1.17-1.82)。

临床怎么用

  • DLL3高表达SCLC二线治疗中不应选用Rova-T替代拓扑替康,因前者OS更差。
  • 使用Rova-T时需关注浆膜腔积液、光敏反应及外周水肿。
  • 该人群二线治疗仍需探索更有效方案。

局限性

  • 研究因Rova-T组OS更短被独立数据监查委员会建议停止入组。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: DLL3, an atypical Notch ligand, is expressed in SCLC tumors but is not detectable in normal adult tissues. Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate containing a DLL3-targeting antibody tethered to a cytotoxic agent pyrrolobenzodiazepine by means of a protease-cleavable linker. The efficacy and safety of Rova-T compared with topotecan as second-line therapy in patients with SCLC expressing high levels of DLL3 (DLL3-high) was evaluated. METHODS: The TAHOE study was an open-label, two-to-one randomized, phase 3 study comparing Rova-T with topotecan as second-line therapy in DLL3-high advanced or metastatic SCLC. Rova-T (0.3 mg/kg) was administered intravenously on day 1 of a 42-day cycle for two cycles, with two additional cycles available to patients who met protocol-defined criteria for continued dosing. Topotecan (1.5 mg/m2) was administered intravenously on days 1 to 5 of a 21-day cycle. The primary end point was overall survival (OS). RESULTS: Patients randomized to Rova-T (n = 296) and topotecan (n = 148) were included in the efficacy analyses. The median age was 64 years, and 77% had the extensive disease at initial diagnosis. The median OS (95% confidence interval) was 6.3 months (5.6-7.3) in the Rova-T arm and 8.6 months (7.7-10.1) in the topotecan arm (hazard ratio, 1.46 [95% confidence interval: 1.17-1.82]). An independent data monitoring committee recommended that enrollment be discontinued because of the shorter OS observed with Rova-T compared with topotecan. Safety profiles for both drugs were consistent with previous reports. CONCLUSIONS: Compared with topotecan, which is the current standard second-line chemotherapy, Rova-T exhibited an inferior OS and higher rates of serosal effusions, photosensitivity reaction, and peripheral edema in patients with SCLC. A considerable unmet therapeutic need remains in this population.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Blackhall F, Jao K, Greillier L, et al. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. J Thorac Oncol. 2021. PMID: 33607312. doi:10.1016/j.jtho.2021.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。